Evitrade Health Systems Corp. signed a binding letter of intent as it reached a definitive deal to acquire Hemp Extraction Technology Corp.
The Canadian healthcare technology company had signed a nonbinding letter of intent in August to buy HETC.
As part of the deal, Evitrade will acquire all outstanding shares of HETC in exchange for 23,333,333 Evitrade shares, priced at 30 Canadian cents apiece.
The closing of the deal is subject to Evitrade completing due diligence with HETC. Following the completion of the deal Hemp will become a wholly owned subsidiary of Evitrade.
Evitrade's CEO C.K. Cheung said that HETC's extraction technology and expertise will help deliver medical grade ingredients for the company's health technology developments. HETC is engaged in extracting medical-grade oils from industrial hemp.
Canada-based Evitrade is a technology company specializing in the life sciences sector and is focused on four main areas — autonomous medical care, molecular biology, nutraceutical solutions and genetic selection.